These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38614301)

  • 1. Burning down the house: Pyroptosis in the tumor microenvironment of hepatocellular carcinoma.
    Cheng C; Hsu SK; Chen YC; Liu W; Shu ED; Chien CM; Chiu CC; Chang WT
    Life Sci; 2024 Jun; 347():122627. PubMed ID: 38614301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the Sorafenib-resistant Liver Cancer Microenvironment by Using 3-D Spheroids.
    Sariyar E; Firtina Karagonlar Z
    Altern Lab Anim; 2023 Sep; 51(5):301-312. PubMed ID: 37555318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
    Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
    Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
    Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
    Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
    Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
    Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
    Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
    Hage C; Hoves S; Strauss L; Bissinger S; Prinz Y; Pöschinger T; Kiessling F; Ries CH
    Hepatology; 2019 Oct; 70(4):1280-1297. PubMed ID: 31002440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy modulation attenuates sorafenib resistance in HCC induced in rats.
    Elleithi Y; El-Gayar A; Amin MN
    Cell Death Dis; 2024 Aug; 15(8):595. PubMed ID: 39152108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
    Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
    Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
    Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
    Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.